Document is current
Any future updates will be listed below
-
Authors
Ghosh, Shrestha https://orcid.org/0000-0003-1861-8581
Nguyen, Mileena T. https://orcid.org/0009-0002-8087-1879
Choi, Ha Eun
Stahl, Maximilian
Kühn, Annemarie Luise https://orcid.org/0000-0002-0158-8286
Van der Auwera, Sandra https://orcid.org/0000-0002-1757-7768
Grabe, Hans J.
Völzke, Henry
Homuth, Georg https://orcid.org/0000-0001-6839-0605
Myers, Samuel A. https://orcid.org/0000-0001-7636-0887
Hogaboam, Cory M. https://orcid.org/0000-0003-3366-4850
Noth, Imre
Martinez, Fernando J. https://orcid.org/0000-0002-2412-3182
Petsko, Gregory A. https://orcid.org/0000-0003-3668-3694
Glimcher, Laurie H. https://orcid.org/0000-0002-4971-0404
- License Information
-
More Information
Article History
Received: 11 September 2023
Accepted: 2 August 2024
First Online: 20 August 2024
Competing interests
: L.H.G. is a former Director of Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals and the Waters Corporation and currently serves on the Board of Directors of Analog Devices, Inc. She also serves on the scientific advisory boards of Repare Therapeutics and Abpro Therapeutics. L.H.G. is a consultant for JP Morgan healthcare. G.A.P. is on the Scientific Advisory Boards of Amicus Therapeutics, MeiraGTx, Annovis Bio, Retromer Therapeutics, and Proclara Biosciences and holds equity or stock options in Denali Therapeutics, MeiraGTx, Annovis Bio, Retromer Therapeutics and Proclara Biosciences, companies that are developing therapies for neurodegenerative diseases. M.S. served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK and Rigel; consulted for Boston Consulting and Dedham group and participated in GME activity for Novartis, Curis Oncology, Haymarket Media and Clinical care options. C.M.H. serves as Chief Scientist at Lung Therapeutics and is on the Scientific Advisory Boards of Lassen Therapeutics, Rubedo Life Sciences, and Structure Therapeutics. C.M.H holds stocks options in Lung Therapeutics, Lassen Therapeutics, and Rubedo Life Sciences. I.N. is a consultant for Boerhinger and Sanofi. H.J.G. has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag. All other authors declare no relevant competing interests. L.H.G. and S.G. have a patent filed with Dana-Farber Cancer Institute, Boston related to this work. The remaining authors declare no competing interests.
